The American Diabetes Association is advising doctors and patients not to use compounded GLP-1s due to uncertainty about their content, safety, quality, and effectiveness. The ADA’s statement seeks to provide guidance for health care professionals and people with diabetes and/or obesity. “These medications are critical not just for diabetes and weight management, but also for mitigation of cardiovascular and kidney disease risks in high-risk individuals,” said Dr. Joshua J. Neumiller, the ADA’s president-elect, health care & education and the statement’s lead author. “We urge health care professionals to consider this guidance statement due to concerns around the safety, quality, and effectiveness of compounded versions of these products.” “It is important to consider this guidance as use of incretin-based therapies continues to expand. As demand continues to increase, it is possible that intermittent shortages may occur. We encourage health care professionals and people living with diabetes and obesity to consider this guidance in conjunction with clinical judgment and individual preferences when making informed care decisions,” said Dr. Nuha ElSayed, the ADA’s senior vice president, health care improvement and the manuscript’s senior author. The Fly notes that the decision could be negative for Hims & Hers (HIMS) as well as LifeMD (LFMD).
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on HIMS:
- Hims & Hers price target raised to $38 from $28 at Canaccord
- Trump Weekly: Autos, retail, restaurant sectors brace for import tariffs
- Hims & Hers rises 14.0%
- Trump Trade: Carmakers slip after 25% tariff threat on Mexico, Canada
- Hims & Hers (HIMS) Shares Surge 24% on Makary’s FDA Nomination
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
